康艾注射液联合米托蒽醌及阿糖胞苷方案治疗急性髓系白血病临床观察  

Clinical Observation of Kangai Injection Combined with Therapy of Mitoxantrone and Cytosine Arabinoside for Acute Myeloid Leukemia

作　　者：刘春霞[1] 姚小健[1] 赵龙[1] 刘蓓[1] 成娟[1] 

机构地区：[1]兰州大学第一附属医院血液科,甘肃兰州730000

出　　处：《新中医》2018年第1期85-87,共3页New Chinese Medicine

基　　金：甘肃省中医药管理局课题(GZK-2014-27)

摘　　要：目的:观察康艾注射液联合米托蒽醌及阿糖胞苷(MA)方案与单纯使用MA方案治疗急性髓系白血病的临床疗效。方法:将纳入观察的82例急性髓系白血病患者随机分为联合组与对照组。对照组单纯使用MA化疗方案进行治疗,联合组在对照组治疗方案的基础上加用康艾注射液治疗,治疗2疗程后,观察2组临床总体疗效,观察比较2组白细胞最低值,白细胞恢复正常时间,骨髓抑制、消化道反应、感染、全因病死发生率等。结果:2组临床疗效比较,总有效率联合组80.95%,对照组60.00%,2组临床疗效比较,差异有统计学意义(P<0.05)。2组骨髓抑制期血象变化情况比较,治疗后,2组白细胞计数最低值及白细胞恢复正常时间分别比较,差异均有统计学意义(P<0.01)。联合组优于对照组。2组消化道反应发生率、骨髓抑制发生率分别比较,差异均有统计学意义(P<0.01);2组感染发生率、全因病死率分别比较,差异均无统计学意义(P>0.05)。结论:康艾注射液联合MA方案可以有效地缓解急性白血病患者的临床症状,且可以降低胃肠道反应及骨髓抑制的发生率。Objective：To observe the clinical effect of Kangai injection combined with the therapy of mitoxantrone and cytosine arabinoside（MA） as well as the pure MA therapy for acute myeloid leukemia.Methods：Divided 82 cases of patients who were included in observation with acute myeloid leukemia into the combination group and the control group randomly.The control group was simply given the MA therapy,while the combination group additionally received Kangai injection therapy.Observed the total clinical effect after 2 courses of treatment.Observed and compared the minimum leukocyte,the recovery time of leukocyte,myelosuppression,gastrointestinal reaction,infection,and the incidence of all-cause mortality in both groups.Results：The total effective rate was 80.95% in the combination group and 60.00% in the control group,the difference being significant（P〈0.05）.Compared the hemograms in myelosuppression period of both groups.After treatment,respectively compared the minimum leukocyte and the recovery time of leukocyte between the two groups,differences being significant（P〈0.01）.The combination group was superior to the control group.Compared the incidence of gastrointestinal reaction and myelosuppression in both groups respectively,differences being significant（P〈0.01）.Compared the incidence of infection and all-cause mortality rate between the two groups,there being no significance in differences（P〈0.05）.Conclusion： The application of Kangai injection combined with the therapy of mitoxantrone and cytosine arabinoside can effectively relive the clinical symptoms of patients with acute myeloid leukemia,and reduce the incidence of gastrointestinal reaction and myelosuppression.

关 键 词：急性髓系白血病 康艾注射液 米托蒽醌 阿糖胞苷 

分 类 号：R733.7[医药卫生—肿瘤]